Sanjal H. Desai

Sanjal H. Desai

Hematology | Oncology

909 Fulton Street Southeast
Minneapolis, MN 55455

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin.

Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin.

Journal: Blood cancer journal

Published: February 02, 2026

Impact of Novel Therapies on the Efficacy of Post-Transplantation Brentuximab Vedotin Maintenance in Hodgkin Lymphoma.

Impact of Novel Therapies on the Efficacy of Post-Transplantation Brentuximab Vedotin Maintenance in Hodgkin Lymphoma.

Journal: Blood advances

Published: October 10, 2025

Impact of novel therapies on the efficacy of posttransplantation brentuximab vedotin maintenance in Hodgkin lymphoma.

Impact of novel therapies on the efficacy of posttransplantation brentuximab vedotin maintenance in Hodgkin lymphoma.

Journal: Blood advances

Published: October 10, 2025

Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphoma.

Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphoma.

Journal: Blood cancer journal

Published: July 15, 2025

PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma.

PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma.

Journal: Blood

Published: June 04, 2025

PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma.

PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma.

Journal: Blood

Published: June 04, 2025

Phase 2 study of alemtuzumab and dose-adjusted EPOCH-R in relapsed or refractory aggressive B-cell lymphomas.

Phase 2 study of alemtuzumab and dose-adjusted EPOCH-R in relapsed or refractory aggressive B-cell lymphomas.

Journal: Leukemia & lymphoma

Published: February 03, 2025

Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers.

Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers.

Journal: Blood cancer journal

Published: November 25, 2024

Cardiovascular Considerations After Cancer Therapy: Gaps in Evidence and JACC: CardioOncology Expert Panel Recommendations.

Cardiovascular Considerations After Cancer Therapy: Gaps in Evidence and JACC: CardioOncology Expert Panel Recommendations.

Journal: JACC. CardioOncology

Published: August 07, 2023

Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era.

Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era.

Journal: Blood advances

Published: July 19, 2023

Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes.

Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes.

Journal: Haematologica

Published: January 19, 2023

Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma.

Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma.

Journal: American journal of hematology

Published: November 07, 2022

Showing 1-12 of 26

Last Updated: 09/26/2026